A2ML1

Across TCGA pan-cancer cohorts, A2ML1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of A2ML1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where A2ML1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types A2ML1 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LSCC, and PDAC are the cancer types where A2ML1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in A2ML1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−2.410	<.001	11	view →
LSCC	All	III,IV	+1.969	<.001	9	view →
PDAC	All	All	+1.272	<.001	6	view →
LUAD	All	III,IV	−0.636	.010	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

A2ML1–HNSC

Open the HNSC breakdown →